Epstein Secrets

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

p multiplexed PCR-LDR assays for Category=A Biothreat agents, including all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Congo=nbsp;hemorrhagic fever virus, Lassa fever virus, Rift Valley fever vir=s, Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manu

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

abling simultaneous identification of the pathogens. The assay wa= evaluated on 32 different isolates associated with VHF (ebolavirus,4>marburgvirus Crimean Congo hemorrhagic fever virus, Lassa fever =irus, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia vir

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

ng simultaneous identification of the pathogens. The assay was=evaluated on 32 different isolates associated with VHF (ebolavirus,&nb=p;marburgvirus Crimean Congo hemorrhagic fever virus, Lassa fever viru=, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia vir